Prolor has entered into an evaluation and option agreement with Yeda. Under the terms of the agreement, Prolor may obtain from Yeda a license to develop a number of peptide drug candidates (including an anti-obesity peptide) utilizing a delivery technology developed at the Weizmann Institute.
Shai Novik, president of Prolor, said: “The Weizmann Institute produces world-class research and this agreement, enabling us to access novel technology developed by their scientists, represents an exciting opportunity for Prolor.
“The first preclinical drug candidate we will evaluate under the agreement is a potential long-acting anti-obesity compound. Obesity represents a large and growing worldwide health care crisis, and there is an urgent need for effective and safe weight loss therapies. We believe the timing is right for us to explore entering this market with a drug candidate that may have strong competitive advantages over other anti-obesity approaches currently in development,” he added.